Medication
Compounded tirzepatide is prepared by licensed compounding pharmacies on a per-patient basis. Not FDA-approved as a finished product. April 2026 FDA guidance applies to advertising and clinical use. Pricing in patient-direct telehealth typically ranges $249–$499/month.
| Generic name | tirzepatide |
| Brand manufacturer | 503A and 503B compounding pharmacies |
| FDA indication | Compounded — not FDA-approved as a finished drug |
| FDA approval year | N/A (compounded) |
| Form | Subcutaneous injection (multi-dose vial + syringe) |
| Schedule | Once weekly |
| List price (cash) | $249/month |
For drug-class comparisons, see our medication-comparison hub:
Coverage varies significantly by carrier and employer plan. See our insurance hub for plan-specific guidance:
Compounded Tirzepatide is the brand name for tirzepatide, manufactured by 503A and 503B compounding pharmacies. Compounded tirzepatide is prepared by licensed compounding pharmacies on a per-patient basis. Not FDA-approved as a finished product. April 2026 FDA guidance applies to advertising and clinical use. P
Compounded Tirzepatide list price is approximately $249/month. Insurance may cover it with prior authorization for FDA-approved indications.
Not FDA-approved (compounded). Indication: Compounded — not FDA-approved as a finished drug.
Doses available: Custom titration: typical 2.5 mg → 15 mg weekly. Schedule: Once weekly. Always follow your prescribing clinician's titration plan.
See our medication comparisons hub for head-to-head pages on Wegovy vs Zepbound, Ozempic vs Wegovy, and semaglutide vs tirzepatide.
Note: This page is an editorial overview, not medical advice. Always consult a licensed clinician about whether Compounded Tirzepatide is appropriate for you.